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Since 2004, a total of 131 isolates of Streptococcus 
pneumoniae multidrug-resistant invasive serotype 8 have 
been detected in Spain. These isolates showed resistance to 
erythromycin, clindamycin, tetracycline, and ciprofloxacin. All 
isolates were obtained from adult patients and shared a com-
mon genotype (sequence type [ST]63; penicillin-binding pro-
tein 1a [pbp1a], pbp2b, and pbp2x gene profiles; ermB and 
tetM genes; and a ParC-S79F change). Sixty-eight isolates 
that required a ciprofloxacin MIC ≥16 µg/mL had additional 
gyrA gene changes. Serotype 8-ST63 pbp2x sequences 
were identical with those of antimicrobial drug–susceptible 
serotype 8-ST53 isolates. Serotype 8-ST63 pbp2b sequenc-
es were identical with those of the multidrug-resistant Swe-
den 15A-ST63 clone. Recombination between the capsular 
locus and flanking regions of an ST53 isolate (donor) and 
an ST63 pneumococcus (recipient) generated the novel 15A-
ST63 clone. One recombination point was upstream of pbp2x 
and another was within pbp1a. A serotype 8-ST63 clone was 
identified as a cause of invasive disease in Spain.
Streptococcus pneumoniae is a frequent cause of commu-nity-acquired pneumonia, meningitis, bacteremia, and 
otitis media in children. The diverse biochemical composi-
tion of the capsular polysaccharide results in >94 serotypes 
(1). However, only a few serotypes cause most invasive dis-
ease episodes worldwide. Serotype 8 pneumococci cause 
invasive pneumococcal disease in adults and have been oc-
casionally associated with outbreaks. Nevertheless, isolates 
of this serotype are rarely found in children as a cause of 
invasive disease or as colonizers of the nasopharynx (2,3). 
Few lineages have been identified among serotype 8 pneu-
mococci; the major  clone is Netherlands 8-ST53, which 
has been detected worldwide and is typically susceptible to 
antimicrobial drugs (4).
The capsular polysaccharide is the major virulence 
factor of pneumococci and usually determines their abil-
ity to act as invasive or colonizing microorganisms (3). In 
addition to exhibiting the capsule, pneumococci can show 
low or high genetic diversity, but genotype–serotype asso-
ciation is common. However, this association could be dis-
rupted because of capsular switching caused mainly by re-
combination of capsular genetic loci. This finding could be 
a sporadic event, but the recombinant occasionally spreads 
and could cause pneumococcal disease.
Capsular switching was associated with emergence 
of a serotype 19A variant of a formerly serotype 4 clone 
(5) related to immunity pressure sustained after a 7-valent 
pneumococcal conjugate vaccine was introduced into the 
United States. This well-known phenomenon was the ori-
gin of the major penicillin-resistant clone (serotype 14 vari-
ant of the Spain 9V-ST156 clone), which caused invasive 
pneumococcal disease in Spain in the 2000s (4,6).
Data from the Spanish Reference Laboratory for Pneu-
mococci, which has received pneumococci from Spain 
since 1979, showed rates of 2.5% to 6.5% for serotype 8 
invasive isolates in the last 3 decades. These rates did not 
show any association with introduction of therapeutic or 
preventive measures (7,8). Over these decades, serotype 
8 pneumococci were usually susceptible to antimicrobial 
drugs, although some isolates were resistant to erythro-
mycin or tetracycline. Moreover, serotype 8 pneumococci 
were isolated mainly from adult patients (7,8). However, 
since 2004, serotype 8 pneumococci have been identified 
that showed resistance to erythromycin, clindamycin, tetra-
cycline, and ciprofloxacin.
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In the present study, we analyzed the evolution and 
molecular epidemiology of these multidrug-resistant se-
rotype 8 pneumococci. We determined whether the in-
crease in these isolates was associated with dissemination 
of a new recombinant clone (serotype 8-ST63) capable of 




Isolates received at the Spanish Reference Laboratory 
for Pneumococci were serotyped by using the quellung 
reaction and antisera provided by the Staten Serum Insti-
tute (Copenhagen, Denmark) (8). During January 2004–
December 2012, this laboratory received 22,228 invasive 
pneumococcal isolates (4,274 from children <15 years of 
age, 16,506 from persons ≥15 years of age,  and 448 from 
persons for whom age data were not available). Of these 
isolates, 767 were serotype 8 (3.2%). The proportion of se-
rotype 8 was 4.4% among isolates from adults and 0.4% 
among isolates from children (8). Of the 767 serotype 8 
pneumococci, 131 isolates were resistant to ≥3 antimicro-
bial drugs (all isolates were from adults). Of these isolates, 
119 were available for molecular characterization.
Reference Strains
American Type Culture Collection (ATCC) BAA-661, 
the reference strain of the Sweden 15A-ST63 clone (resis-
tant to erythromycin, clindamycin, and tetracycline, and 
decreased susceptibility to penicillin), was used as a con-
trol for pulsed-field gel electrophoresis (PFGE) and PCR–
restriction fragment length polymorphism (PCR-RLFP) 
analysis of penicillin-binding protein (PBP) genes. Strains 
CSUB8370, CSUB8757, and CSUB5364 (all 3 strains are 
serotype 8, susceptible to antimicrobial drugs, and ST53) 
were also used as controls for PFGE and PCR-RFLP of 
PBPs (4,9,10).
Antimicrobial Drug Susceptibility Testing
MICs of antimicrobial drugs for drug-resistant isolates 
were determined by using the microdilution method, 2%–
5% lysed horse blood, and commercially available panels 
(STRHAE1; Sensititre, East Grunstead, UK) and following 
the recommendations of the Clinical Laboratory Standards 
Institute  (11,12). S. pneumoniae ATCC 49619 was used 
for quality control testing. When ciprofloxacin or levoflox-
acin MICs were >2 µg/mL, these MICs were tested by us-
ing the E test (AB Biodisk, Solna, Sweden).
Molecular Typing
Genomic DNA was embedded in agarose plugs and 
digested with SmaI. Fragments were separated by PFGE in 
a CHEF-DRIII apparatus (Bio-Rad, Hercules, CA, USA as 
described (9). PFGE patterns were compared visually with 
patterns of reference and control strains. Seventeen strains 
selected from different areas and years were studied by 
using multilocus sequencing typing (MLST) as described 
(13). Allele numbers and sequence types (STs) were as-
signed by using the pneumococcal MLST website (http://
www.mlst.net).
PBP Fingerprinting
The analysis of pbp1a, pbp2b, and pbp2x genes was 
performed by using PCR-RFLP. We used primers de-
scribed by du Plessis et al. (14) for pbp1a and those de-
scribed by Gherardi et al. (15) for pbp2b and pbp2x. PCR 
products were digested with HinfI, and digestion patterns 
were visually compared. In addition, both strands of PCR 
PBP gene products of 3 selected strains were purified and 
sequenced by using amplification primers for pbp2b and 
pbp2x. For pbp1a amplification, primers and PBP1ASq1 
(5′-TAAGGTCTACATGTCTAAT-3′) were used for se-
quencing purposes.
Resistance Phenotype Characterization
The presence of macrolide resistance genes (ermB, 
mefA/E) and the tetracycline resistance gene (tetM) was 
tested by PCR described elsewhere (16). To characterize 
quinolone resistance for all strains, we used a PCR-RFLP 
method that detects point mutations at the main quinolone 
resistance determinant region (QRDR) positions (17,18). 
In brief, after PCR amplification, parC amplicons were di-
gested with HinfI or SfaNI to detect changes in S79 or D83, 
respectively. PCR products of parE were digested with 
HinfI to detect changes in D435. Finally, gyrA amplicons 
were digested with HinfI (S81) or MboII (E85) (17,18). 
Control strains with known QRDR mutations were used in 
each run (19).
PCR Amplification and DNA Sequencing and Analysis
QRDRs sequences were determined for 43 strains (15 
with low-level ciprofloxacin resistance [LLCipR] [MIC 
≤8 µg/mL] and 28 with high-level ciprofloxacin resistance 
[HLCipR] [MIC ≥16 µg/mL)]. In brief, gyrA, parC, parE, 
and gyrB genes were amplified by using PCR and primers 
and conditions previously described (19). PCR products 
were purified, and both strands were sequenced by using 
primers for PCR amplification (19).
Analysis of Recombination Site Upstream of pbp2x
We used sequence alignments of ≈20 kb located up-
stream of the pbp2x gene of 2 serotype 8 (ST53) strains 
(2071247 [GenBank accession no. ALBK01000004); and 
2081685 [ALBN01000001]), 1 serotype 15A (ST63) strain 
(GA47179 [AIKX01000002]), and strain G54 (serotype 
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19F, ST63, CP001015) (20) pneumococcal genomes to 
design 7 sets of PCR primers. These primers were used 
to identify the putative recombination event upstream of 
pbp2x (Table).
Results
Description and Spread of Multidrug-Resistant Strain
During 2003–2012, among invasive strains collected 
from adults, the prevalence of serotype 8 ranged between 
3.6% and 5.0% (Figure 1). In 2004, four invasive mul-
tidrug-resistant serotype 8 isolates were detected at the 
Spanish Reference Laboratory from 3 hospitals in Madrid 
(central Spain). Multidrug-resistant serotype 8 isolates 
were also detected in eastern (2005), southern (2006), 
and northwestern (2007) Spain. During 2009-2012, 
multidrug-resistant serotype 8 isolates were detected 
among invasive isolates from 7 autonomous communi-
ties. In the Madrid area, serotype 8-ST63 isolates were 
detected mainly in adult HIV-infected patients (21). All 
multidrug-resistant serotype 8 isolates were from adults 
(78.7% from male patients). Sources of isolation of mul-
tidrug-resistant serotype 8 pneumococci were blood (n = 
116), pleural fluid (n = 6), cerebrospinal fluid (n = 2), 
fluid from eyes with endophthalmitis (n = 6), and abscess 
fluid (n = 1).
All 131 multidrug-resistant serotype 8 pneumococci 
were susceptible to penicillin (MIC <0.03 µg/mL), cefo-
taxime (MIC <0.03 µg/mL), and amoxicillin (MIC <0.06 
µg/mL) and resistant to erythromycin (MIC >128 µg/
mL), clindamycin (MIC >128 µg/mL), and tetracycline 
(MIC >64 µg/mL). Ciprofloxacin MICs ranged from 
2 µg/mL to 64 µg/mL, and 68 strains showed HLCipR 
(MIC ≥16 µg/mL).
Molecular Typing
A common PFGE pattern (nearly identical to that of 
the reference Sweden 15A-ST63 clone) was found among 
all 119 available serotype 8 isolates with multidrug resis-
tance, which suggested a capsular switching event. This 
PFGE pattern was different from those of other antimicro-
bial drug–susceptible serotype 8-ST53 isolates (related to 
the Netherlands 8-ST53 clone) (Figure 2, panel A). These 
PFGE patterns were confirmed after MLST characteriza-
tion of 17 selected multidrug-resistant serotype 8 isolates 
(all were ST63).
PBP Typing and Analysis
Results of PCR-RFLP analysis of pbp1A, pbp2b, and 
pbp2x genes of serotype 8-ST63 and antimicrobial drug–
susceptible serotype 8-ST53 and of the multidrug-resistant 
Sweden 15A-ST63 reference strain (ATCC BAA-661) are 
shown in Figure 2, panel B. Amino acid sequence varia-
tion of the PBP1A, PBP2B, and PBP2X proteins of the 
epidemic strain and 2 control strains is shown in Figure 
2, panel C. All serotype 8-ST63 isolates showed the same 
restriction profile for each pbp gene analyzed, which sug-
gested clonal homogeneity. The restriction profile of pb-
p2b of the new strain was identical with that of the Swe-
den 15A-ST63 clone and different from those of serotype 
8-ST53 drug-susceptible strains according to PCR-RFLP 
results. These results were confirmed after sequencing 
the pbp2b gene amplicons of 3 serotype 8-ST63 isolates, 
the Sweden 15A-ST63 reference strain, and 2 serotype 
8-ST53 isolates (Figure 2, panel C).
The PCR-RFLP profile of pbp2x of serotype 8-ST63 
isolates was identical with those of serotype 8-ST53 isolates 
(related to the Netherlands 8-ST53 clone) and different from 
that of the Sweden 15A-ST63 reference strain. These results 
were confirmed after sequencing the pbp2b gene amplicons 
of 3 serotype 8-ST63 isolates, the Sweden 15A-ST63 refer-
ence strain, and the serotype 8-ST53 isolates.
 
Table. Primers used to map the putative recombination event 
upstream of the pbp2x gene of Streptococcus pneumoniae, 
Spain, 2004–2012* 
Primer Sequence, 53 Position† 
F1 AAATCCGAAGAAGGCCAAAT 278234–278253 
R1 GTACTTGAGATTGGCGTGTTTG 278834–278813 
F2 TCAATGACTGTGATGCCTGTT 290699–290719 
R2 TGTCAGACAAATAGGACAAGGAGA 291315–291292 
F3 GTCAATGACACCAACCTCTTG 282168–282188 
R3 GCTATGAGCCATTCTAGCAAAGA 283037–283015 
F4 TGAATGTAAAGACACACGAGGAA 273278–273300 
R4 CAGTGATAACGAATACCATACAGAA 274128–274104 
F5 CAGCTCTATGAACACCGGACT 289177–289197 
R5 TTCCTAGTCGTAACCATCATTTCA 289927–289904 
F6 CCTTGGATACGGGTATTCGTT 287148–287168 
R6 GCAGTCGCTTGACCTTTTCT 287756–287737 
F7 GTGGACAGGAAGCAAAGCTC 275192–275211 
R7 GGCAGTCAGATTTGCAGACA 276056–276037 
*The penicillin-binding protein 2x gene (pbp2x) (SPG_0305) of S. 
pneumoniae G54 strain (serotype 19F-ST63; GenBank accession no.  
CP001015) is located between positions 292638 and 294890 of its 
genome. F, forward; R, reverse. 
†Corresponding to the genome of the G54 strain. 
 
Figure 1. Streptococcus pneumoniae serotype 8 among invasive 
pneumococci isolated from adults in Spain, 2003–2012.
RESEARCH
 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 20, No. 11, November 2014 1851
All serotype 8-ST63 isolates had the same PCR-RFLP 
profile for pbp1a. This profile was different from those of 
antimicrobial drug–susceptible serotype 8-ST53 and nearly 
identical with the profile of Sweden 15A-ST63. Nucleotide 
sequence variation in the pbp1a gene of serotype 8-ST53, 
serotype 8-ST63, and Sweden 15A-ST63, determined by 
using S. pneumoniae R6 as a reference, is shown in Figure 
3. Using R6 nomenclature for the pbp1a gene, we found that 
sequences of serotype 8-ST63 and Sweden 15A-ST63 were 
identical for nt 1–1341. Sequences of serotype 8-ST53, se-
rotype 8-ST63, and Sweden 15A-ST63 were identical at 
nt 1342–1353. Sequences of pbp1a for nt 1354–1970 of 
serotype 8-ST63 were identical with those of antimicrobial 
drug–susceptible serotype 8-ST53. These results suggest 
that a recombination point was located in the 3′ end of the 
pbp1a gene.
Recombination Event Upstream of pbp2x
To determine the position of the recombination event 
that gave rise to the serotype 8-ST63 strain, we searched the 
public databases for genomic sequences located upstream 
of the pbp2x gene corresponding to serotype 8-ST53 and 
Figure 2. A) Pulsed-field gel electrophoresis patterns of chromosomal DNA of Streptococcus pneumoniae isolates after digestion with 
SmaI. Lane 1, Sweden 15A-ST63 (American Type Culture Collection [ATCC] BAA-661); lanes 2−5, serotype 8-ST63; lanes 6 and 7, 
serotype 8-ST53; lane M, molecular mass markers. B) PCR–restriction fragment length polymorphism patterns of penicillin-binding protein 
genes pbp1A, pbp2b, and pbp2x. Lane 1, Sweden 15A-ST63 (ATCC BAA-661) lanes 2−4: serotype 8-ST63; lanes 5 and 6, serotype 
8-ST53. C) Amino acid sequence variations among PBP1A, PBP2B, and PBP2X proteins. Row 1, S. pneumoniae R6; row 2, serotype 
8-ST53; row 3, serotype 8-ST63; row 4, Sweden 15A-ST63 reference strain. Codon numbers of polymorphic sites are numbered in a 
vertical format. Amino acids are numbered according to their positions in the corresponding protein. Only those amino acids that differ 
from those of the strain R6 sequence are shown. Dots indicate an amino acid residue that is identical with that in the strain R6 sequence.
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serotype 15A-ST63 pneumococcal strains. Draft genomic 
sequences of 2 serotype 8-ST53 strains (2071247 
[ALBK01000004]) and 2081685 [ALBN01000001]) were 
found. These sequences differed only at 5 positions in an 
≈20-kb region. The draft sequence of the genome of a single 
serotype 15A-ST63 (strain GA47179 [ AIKX01000002]) 
was also used. Moreover, when we compared this sequence 
(serotype 15A-ST63) with complete genomes of S. pneu-
moniae strains, we found an excellent match with that of 
strain G54 (serotype 19F; ST63); only 2 nt changes oc-
curred in a 20,792-bp overlap.
The G54 strain has been shown to be a type 19F trans-
formant of a serogroup 15 isolate (20). Nucleotide align-
ment of the 4 strains mentioned above showed several 
polymorphic sites, which enabled clear (although somehow 
limited) discrimination between ST53 and ST63 strains 
(Figure 4, panel A). Different fragments of the ≈20-kb re-
gion located upstream of pbpx2 were amplified by PCR and 
sequenced (Table; Figure 4, panel A). Sequence compari-
sons showed that the recombination event between the do-
nor DNA of a serotype 8 (ST53) strain and a recipient strain 
of serotype 15A (ST63) had occurred in a ≈3.8-kb region 
that contained genes SPG_0286 and SPG_0290 (using the 
strain G54 notation). Further attempts to determine more 
precisely the location of the recombination event were not 
made because this region has only 17 polymorphic sites. A 
scheme of the possible recombination event in which cap-
sular loci and flanking regions (pbp2x and pbp1a) of a se-
rotype 8-ST53 strain were acquired by ST63 pneumococci 
is shown in Figure 4, panel B.
Molecular Characterization of Drug Resistance
The ermB gene (which confers the macrolide–lin-
cosamide–streptogramin B phenotype) and the tetM gene 
(which confers tetracycline resistance) were detected by 
PCR. Both genes are usually present in pneumococci related 
to the Sweden 15A-ST63 clone (16). These genes are located 
in the composite element Tn5251 (Figure 4, panel B) (20).
Among 131 serotype 8-ST63 strains, 63 showed LL-
CipR (MICs 2 µg/mL–8 µg/mL) and 68 showed (HLCipR 
(MICs ≥16 µg/mL). An increase in the proportion of se-
rotype 8-ST63 isolates with HLCipR was observed: from 
19.5% (8/41) during 2004-2006 to 86.7% (26/30) during 
2010-2012 (p<0.001). PCR-RFLP analysis showed that 
all 119 available serotype 8-ST63 isolates that were stud-
ied lacked the restriction site for HinfI in parC, which is 
Figure 3. Nucleotide sequence variations in the penicillin-binding protein 1A (pbp1a) gene of Streptococcus pneumoniae. Row 1, 
S. pneumoniae R6; row 2, serotype (Ser) 8-ST53; row 3, serotype 8-ST63; row 4, Sweden 15A-ST63 reference strain. Polymorphic sites 
are numbered in a vertical format. Nucleotides are numbered according to their positions in the gene. Only polymorphic sites are shown. 
Dots indicate a nucleotide that is identical to that in the R6 sequence. The putative recombination site is shaded in gray.
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associated with a change in S79. This change was con-
firmed to be an S79F after sequencing 43 isolates (15 LL-
CipR and 28 HLCipR). Fifty-nine of 61 available LLCipR 
isolates (all with the S79 change) had levofloxacin MICs 
≤2 µg/mL (susceptible).
A total of 58 of 68 HLCipR isolates were available for 
analysis. Of these 58 isolates, 47 lacked the HinfI restric-
tion site in gyrA, which is associated with a mutation at 
S81; 10 isolates lacked the MboII restriction site related to 
a gyrA change at E85; and 1 isolate lacked the HinfI and 
MboII restriction sites that were assumed to be caused by 
changes in S81 and E85 in gyrA. The results of gyrA QRDR 
sequencing of 28 selected HLCipR isolates showed various 
gyrA changes (S81F [n = 23]; S81Y [n = 2]; E85K [n = 3]; 
and S81F and E85K [n = 1 each]). No parE changes were 
detected by PCR-RFLP or sequencing. Serotype 8-ST63 
isolates for which QRDRs were sequenced showed poly-
morphisms for parC (G77[GGA]), parE (I460V), and gyrA 
(Y75[TAT]) that were identical with those of the Sweden 
15A-ST63 reference strain and other pneumococci of this 
lineage (21,22).
Discussion
In this study, we described the emergence and spread 
of a pneumococcal clone that originated by recombination 
of a ciprofloxacin-resistant and multidrug-resistant strain 
related to the Sweden 15A-ST63 clone, which acted as a 
recipient of DNA, and a serotype 8 strain with ST53, which 
acted as a donor of DNA. The new recombinant clone (se-
rotype 8-ST63) was initially confined to the metropolitan 
area of Madrid and was mainly associated with HIV-in-
fected patients (21). However, in the past 5 years, the new 
Figure 4. Chromosome location of the recombination region located upstream of the penicillin-binding protein 2x (pbp2x) gene of Streptococcus 
pneumoniae (A) and antimicrobial drug resistance determinants, capsular loci of the putative donor, recipient, and recombinant strains (B). 
In the genomic region upstream of pbp2x (SPG_0305), genes have been named as in the G54 genome (ST63) (GenBank accession no. 
CP001015). Number of polymorphic sites located either within the genes (inserted into the arrows or into black boxes) or in their intergenic 
regions (gray boxes) is shown. The approximate location of the recombination event is indicated by the dotted box. Amplified and sequenced 
fragments are indicated in relationship to primer pair designations (Table). MICs for penicillin (Pen) are shown. 
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clone has been detected in 9 other regions in Spain, which 
indicates an ability to spread. Two characteristics merged 
in this new clone, the invasive disease potential of serotype 
8 and the antimicrobial drug resistance of ST63, which sug-
gested that the recombinant could be a new antimicrobial 
drug–resistant clone.
The capsular polysaccharide is the major factor in de-
termining the invasive disease potential of a given isolate. 
Serotype 8 has been associated with high invasive disease 
potential when a large collection of invasive and colonizing 
isolates were compared (23). Moreover, capsular serotype 
8 was associated with high attack rates; 30 cases of inva-
sive pneumococcal disease/100,000 carriage acquisitions 
were detected (2). Conversely, serotype 15A pneumococci 
show low invasive potential and are usually associated with 
ST63 and resistance to macrolides, clindamycin (ermB) and 
tetracycline (tetM) (2,16). The overall frequency of clonal 
complex (CC) 63 among invasive isolates from adults 
was low: 2.5% (22/899) in 1997–2008 (4). Moreover, in 
3 studies conducted in Spain with quinolone-resistant and 
macrolide-resistant pneumococci, CC63 was 1 of the most 
prevalent clones (16,19,22).
The results of the present study suggest that the new 
strain could be the result of a recombination event between 
a serotype 15A-ST63 pneumococcal isolate that contained 
the S79F change in ParC and a serotype 8-ST53 pneumo-
coccus. In this event, the recombination fragment included 
the pbp2x gene and part of the pbp1a gene. The recombina-
tion of the cps locus and flanking regions has been observed 
by other authors, (6,24,25), which suggests that it is a com-
mon biologic process in the evolution of pneumococci.
The new strain, serotype 8-ST63, is penicillin suscepti-
ble (MIC <0.01 µg/mL), and ST63 isolates with other sero-
types (15F, 15A, 15B, 19F, and 19A) are usually penicillin 
resistant (MIC range 0.12 µg/mL–0.5 µg/mL) (10,16,22). 
The penicillin resistance of CC63 isolates is associated with 
a Q552E change in PBP2X (26). The acquisition of pbp2x 
genes from serotype 8-ST53, without changes involved in 
b-lactam resistance, by the recombinant strain explains its 
penicillin susceptibility.
There have been other examples of recombinant 
clones caused by capsular switching that successfully 
spread. For instance, in the past decade, acquisition of se-
rotype 14 by pneumococci of serotype 9V of ST156 has 
been associated with the worldwide increase of serotype 
14 as a cause of invasive pneumococcal disease (4,6). 
Moreover, exchange of capsular genes with pbp genes has 
been documented in the serotype 19A-ST320 clone that 
spread worldwide and is a major cause of multidrug-resis-
tant invasive and noninvasive disease (27,28). In the Unit-
ed States, recombination of capsular and pbp genes has 
been observed as a vaccine escape of a penicillin-suscep-
tible serotype 4 that acquired the capsular genes and PBPs 
of a serotype 19A strain. This recombinant strain had a 
nonvaccine serotype and an antimicrobial drug resistance 
pattern that favored its spread in the United States. (5). 
To the best of our knowledge, the new recombinant clone 
(serotype 8-ST63) described here has not been detected 
outside Spain.
A report from South Africa described the spread of 
2 quinolone-resistant strains that caused invasive disease 
and colonized children; most of these children were re-
ceiving treatment with antimicrobial drugs (including 
levofloxacin) for multidrug-resistant tuberculosis (29). 
Moreover, in previous studies, our group and others have 
observed some clustered infections, with a limited number 
of cases caused by quinolone-resistant pneumococci in a 
specific geographic area (19,30). The recombinant strain 
(serotype 8-ST63) described in the present study has been 
detected in several cities in Spain, which demonstrates its 
ability to disseminate.
Most isolates of this new clone with ciprofloxacin re-
sistance required MICs of levofloxacin that were in the sus-
ceptible range according to recommendations of the Clini-
cal and Laboratory Standards Institute (12). Because these 
strains had a first-step mutation, use of fluoroquinolones to 
treat infections could become a problem. At least 1 death, 
resulting from  therapeutic failure of levofloxacin, has 
been documented: the patient had pneumococcal pneumo-
nia caused by a serotype 8-ST63 pneumococci in Seville, 
Spain. In this case, the initial strain had the S79F change in 
ParC and required a levofloxacin MIC of 1 µg/mL. After 
levofloxacin therapy, high-level drug resistance developed 
in this strain after a second change in GyrA (31).
In the 1990s, use of antimicrobial drugs was high in 
Spain. During this period, penicillin-resistant and multi-
drug-resistant clones spread over the country, caused in-
vasive disease, and colonized healthy children. Since that 
time, use of antimicrobial drugs has decreased in Spain 
(32). Together with vaccination with the 7-valent pneumo-
coccal conjugate vaccine, the decrease in use of b-lactams 
probably contributed to the recent decrease in penicillin-
resistance and multidrug-resistance rates (4,8). In contrast, 
data from the Spanish Medicines Agency (http//agemed.
es) indicate that levofloxacin consumption has increased 
from 0.2 defined daily doses/1,000 persons/day (DDD) 
in 2002 to 0.4 DDD in 2006 and 0.6 DDD in 2012. This 
antimicrobial drug pressure could have favored spread of 
the fluoroquinolone-resistant clone in Spain and resulted in 
the increase in the proportion of HLCipR among serotype 
8-ST63 isolates.
Children are the main reservoir for pneumococci, 
but quinolones are seldom prescribed for this popula-
tion. Thus, isolation of quinolone-resistant pneumococci 
from children is rare. We have not detected any serotype 
8-ST63 pneumococci in isolates from children. However, 
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in a plausible scenario, the recombinant clone could col-
onize the nasopharynx of children and become a major 
source for dissemination.
In conclusion, emergence and spread of the serotype 
8-ST63 clone that originated by genetic interchange of cap-
sular genes and their flanking regions, including pbp1a and 
pbp2x genes, have been detected in Spain. The 2 clones 
involved in capsular switching were Netherlands 8-ST53 
and Sweden 15A-ST63. Surveillance is needed to clarify 
the dynamics of this new multidrug-resistant clone as cause 
of pneumococcal disease.
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